Unusual case of tacrolimus vascular toxicity after deceased donor renal transplantation.

We report a case of tacrolimus vascular toxicity found on a protocol biopsy shortly after a deceased donor renal transplantation. The patient was immunologically high-risk and acute antibody-mediated rejection during post-transplant dialysis phase was suspected on the protocol biopsy. Although the patient was stable after treatment of rejection, a further examination showed a very rare but specific side-effect of tacrolimus.

Biopsy findings on a stable recipient after secondary donor specific antibody (DSA) positive and ABO incompatible kidney transplantation.

Using desensitization protocol, we performed a secondary donor specific antibody (DSA) positive and ABO incompatible kidney transplantation. One-hour biopsy showed no C4d deposition. The protocol biopsy after 2 weeks showed diffuse C4d deposition with peritubulitis.

[Usefulness of low-dose and long-term administration of imatinib in patients with liver metastases of rectal GIST and GIST of stomach].

Imatinib is an effective drug for KIT positive GIST, and the usual dose is 400 mg/day. On the other hand, imatinib sometimes causes leucopenia and it is hard to maintain a dosage of 400 mg/day. We reported here the two cases with a remarkable response of unresectable GIST using a low-dose and long-term administration of imatinib.

[Usefulness of hepatic arterial infusion chemotherapy for the patients with synchronous liver metastases from colorectal cancer].

We analyzed the results of hepatic arterial infusion chemotherapy (HAIC) for 24 patients with synchronous liver metastases from colorectal cancer for the last twelve years in order to investigate the usefulness of HAIC for those patients. In 8 cases with resection of liver metastases, the median survival time (MST) was 45 months, mean survival time was 53 months and a 5-year survival rate was 44%. In 16 cases without resection of liver metastases, 2 cases had complete response (CR), 10 cases had partial response (PR), 4 cases had stable disease (SD), and the response rate was 75%.

[Usefulness of hepatic arterial infusion chemotherapy for the patients with synchronous liver metastases from colorectal cancer].

We analyzed the results of hepatic arterial infusion chemotherapy (HAIC) for 21 patients with synchronous liver metastases from colorectal cancer for the last ten years to investigate the usefulness of HAIC for those patients. In 7 cases with resection of liver metastases, the median survival time (MST) was 49 months, mean survival time was 56.3 months and a 5-year survival rate was 43%.